About two thirds of people after stroke have some level of disability. Rehabilitation helps to reduce disability and supports people to return to a meaningful life. We know that the more rehabilitation you do especially, within the first six months after stroke, the better the outcome. However, rehabilitation services, especially in the community, are often lacking, non-specialist or provide only a limited number of therapy sessions. Recently national guidelines for care of people after stroke recommend that people receive up to three hours/day of therapy on at least five days/week. NHS services cannot provide this level of therapy so new ways to support people to increase the amount of therapy they do on their own is needed.
The aim of the research is to test a 16 week community, home-based physiotherapy programme to improve the amount of therapy exercise a stroke survivor does, therefore improving the outcome and reducing the level of disability.
Participants will be recruited as they transition from inpatient services to community physiotherapy. Participants will be randomised to either the control or intervention arm. Participants in the intervention arm will take part in a 16-week community, home-based physiotherapy programme. Within the 16-week intervention, participants will receive 5 home based and 4 remote appointments which will comprise of usual physiotherapy assessment and exercise prescription that incorporates 1) Personalised online exercise programme delivered through the Giraffe platform; 2) Goal setting and Action Planning (G-AP); and 3) Supported self-management approaches. Participants will receive an intervention workbook to support them with strategies to achieve their goals and build their self-management skills e.g. how to integrate therapy into their daily life, dealing with barriers, identifying social support networks.
Participants randomised to the control group will receive usual multi-disciplinary rehabilitation from their care team (e.g., physiotherapist, Occupational Therapists, Speech and Language Therapists) as per their NHS Health boards care plan.
The study will measure both feasibility outcomes associated with the implementing the study alongside clinical and wellbeing measures.
To test the feasibility of the study we will assess how many people agree to take part, complete the exercise sessions and complete the outcome measurements. We will also interview people affected by stroke, their significant others if appropriate, and therapists to get their views on the programme. We will do clinical assessments too at four time points across the study looking at walking ability, arm function, level of disability, confidence level, fatigue and quality of life.

开始日期2025-05-01

申办/合作机构

Glasgow Caledonian University

[+4]

NCT06658782

/ RecruitingN/AIIT

Abbreviated Magnetic Resonance Imaging vs Ultrasound Surveillance for Liver Cancer dETection in People at High Risk of Developing Liver Cancer

Aim: To use magnetic resonance imaging (MRI) scans without contrast to help improve diagnosis of liver cancer in people who are at increased risk of developing liver cancer.
Background: People with any condition that affects the liver over a long period of time can develop cirrhosis. Conditions and risk factors that can lead to cirrhosis include alcohol excess, liver steatosis (lipid or fat accumulation in the liver) and infection with the viruses hepatitis B and C. One of the concerns about people with cirrhosis is that they are at increased risk of developing liver cancer. People with cirrhosis are recommended to have an ultrasound scan (USS) every 6 months (surveillance for liver cancer) so that if a cancer develops, it is diagnosed at an early stage when it can be cured. However, ultrasound can miss cancers even in people having scans every 6 months. Furthermore, the risk of cancer is not alike among people with cirrhosis. For example, people with more advanced cirrhosis and those with cirrhosis from hepatitis B are at higher risk. It is therefore possible that better tests than ultrasound are needed for people with cirrhosis who are at particularly high risk of developing cancer.
Computed tomography (CT) and Magnetic Resonance Imaging (MRI) scans with dye injection (contrast) are used for liver cancer diagnosis. However, they cannot be done every 6 months because of costs, capacity and toxicity from high CT radiation doses, and MRI contrast build-up in the brain with repeated MRI contrast injections. MRI scans without contrast are not toxic, could be done in 20 minutes and are cheaper, so could be done every 6 months. In the experience of the study investigators, MRI without contrast may raise suspicion of liver cancer in cases missed by ultrasound, so it could be used for surveillance instead of ultrasound. This study aims to find out if it is feasible to use a quick MRI (20 minutes) without contrast as surveillance for liver cancer in people at high risk of liver cancer due to liver cirrhosis and to compare this MRI with ultrasound.
Design and Methods: The investigators will recruit 300 people at higher risk of developing liver cancer because of cirrhosis. Study participants will have an ultrasound scan every 6 months as they would in their standard clinical care and an additional 6 monthly non-contrast MRI scan for 30 months (6 visits). If the ultrasound or non-contrast MRI raises concern for a possible liver cancer, an MRI scan with contrast (with dye injection) will be done for definitive diagnosis. All participants will have an MRI with contrast at the end of 30 months (M30) to ensure that no cancers were missed. Participants will be asked to complete questionnaires to measure quality of life, anxiety, and their experience of MRI and ultrasound scans and data will be collected from their medical notes. The number of liver cancers detected by ultrasound will be compared to the number detected by the non-contrast MRI scans.

开始日期2025-05-01

申办/合作机构

University of Oxford

[+4]

NCT06865950

/ RecruitingN/A

Sex Differences in Prehospital Acute Management of Suspected Stroke Patients

Background: Stroke is a leading cause for individual, family and societal harm with huge health-economic impact. Immediate and correct prehospital acute stroke pathway initiation is key for treatment success.
Evidence points towards sex inequity in management pathways of acute stroke care. A complicating factor in acute stroke management is the diversity in clinical presentation among patients of different sex. This increases the challenges of correct prehospital identification.
Most of the currently available data on male and female differences in acute stroke management come from patients with hospital-confirmed stroke. Little to no information is available about sex-related management differences of patients with prehospital suspected stroke, often missed by stroke quality databases.
Objectives: To identify sex differences in EMS-delivered prehospital diagnostic accuracy and management of patients with suspected or confirmed acute stroke.
Methods: International project collaboration to conduct a cross-regional cohort analysis of patients with a prehospital working diagnosis of stroke and/or hospital-confirmed stroke diagnosis.
Relevance: More information and details about the reasons for a potential prehospital treatment inequity are a necessary next step for any improvement and subsequent development of structured training programmes for emergency medical service personnel. This project is the first large-scaled international collaboration addressing sex differences in prehospital stroke care. With this approach the project will not only lead to more urgently needed information, but will also serve as a lighthouse project for raising general awareness for this topic.

开始日期2025-05-01

申办/合作机构

Universität des Saarlandes

[+11]

100 项与 Glasgow Caledonian University 相关的临床结果

登录后查看更多信息

0 项与 Glasgow Caledonian University 相关的专利（医药）

登录后查看更多信息

3,700

项与 Glasgow Caledonian University 相关的文献（医药）

2026-01-01·JOURNAL OF PSYCHIATRIC RESEARCH

Efficacy and tolerability of brexpiprazole augmentation of SSRI therapy in PTSD: A systematic review and meta-analysis of randomized controlled trials

Review

作者: Balogun, Mahmood ; Kotochinsky, Martin ; Vieira, Gustavo Hayasaki ; Sherpa, Nima Norbu ; Alessi, Mateus Rodrigues ; Lezana, Andrea Gonzalez

Selective-serotonin re-uptake inhibitors (SSRIs) remain the primary pharmacotherapy for post-traumatic stress disorder (PTSD), yet 50 % of patients achieve insufficient symptomatic relief. Brexpiprazole, a serotonin-dopamine modulator, has emerged as a potential SSRI adjunct, but its benefit-risk profile has not been fully characterized. We searched PubMed, Europe PMC, Web of Science, EMBASE, Cochrane CENTRAL, PsycINFO, EBSCO and ClinicalTrials.gov for randomized-controlled trials (RCT) comparing BRX + SSRI with SSRI ± placebo among PTSD patients. Efficacy was assessed with the CAPS-5 and CGI-S scales, whereas safety was evaluated through rates of weight gain, metabolic laboratory changes, somnolence and any TEAE. Four RCT with 981 patients (51.3 % receiving BRX) met inclusion. Follow-up ranged from 8 to 12 weeks. Statistically significant improvement in CAPS-5 was observed in the BRX + SSRI versus SSRI ± placebo group (MD -3.77; 95 %CI -6.79 to -0.75; p = 0.01). However, pooled CGI-S deemed no statistically significant difference (MD -0.15; 95 %CI -0.33 to 0.04; p = 0.12). In the safety assessment, BRX increased body weight (MD 1.47; 95 %CI 0.84 to 2.09; p < 0.01) and somnolence (RR 2.39; 95 %CI 1.03 to 5.57; p = 0.04). However, the overall incidence of any treatment-emergent adverse event (TEAE) did not differ between the BRX and the control group (RR 0.77; 95 %CI 0.31 to 1.88; p = 0.56). Similarly, metabolic laboratory parameters showed no statistically different results in TGL (MD 2.95; 95 %CI -6.70 to 12.60; p = 0.55). In this meta-analysis, BRX augmentation significantly improved CAPS-5 scores but not CGI-S. Somnolence and weight gain were more frequent, with no changes in metabolic labs. Larger, longer-term RCTs are needed to confirm these findings.

2025-12-31·Global Health Action

‘Mind the gaps’: stakeholder perspectives on addressing antimicrobial resistance in the environment in the Indian context

Article

作者: Connolly, John ; Hursthouse, Andrew ; Mukherji, Soumyo ; Esiovwa, Regina ; Henriquez, Fiona L. ; Cameron, Anishka ; Mukherji, Suparna

BACKGROUND:

There is growing global awareness of the pivotal role environmental factors, including pharmaceutical manufacturing waste, play in the development and spread of antimicrobial resistance (AMR). India bears one of the highest burdens of AMR globally and possesses a substantial manufacturing sector, but limited insight is available on how to practically mitigate environmental AMR-related risk in this context.

OBJECTIVE:

To understand the barriers and opportunities in managing manufacturing waste for addressing AMR in the environment from the perspectives of stakeholders in India.

METHODS:

We conducted semi-structured interviews with a range of stakeholders from government, industry, and civil society following a stakeholder mapping and analysis process within the Indian context. We also undertook a series of stakeholder events to inform the study.

RESULTS:

Our findings indicate that 1) Policy action is fragmentary and there are economic and capacity gaps that have implications for industry behaviours; 2) A One Health approach to addressing AMR in the environment requires leadership and that means AMR prevention needs to be institutionalised within government for them to steer, facilitate and coordinate; and 3) There is a need to enhance knowledge amongst policymakers in India about AMR in the environment, and robust 'evidence' is required to foster policy change.

CONCLUSIONS:

The study underscores the need for a multifaceted strategy to address the contribution of pharmaceutical manufacturing waste to AMR in the environment in India. Greater prioritisation of AMR, stakeholder collaboration, and capacity building are essential to overcoming the challenges identified.

2025-12-31·European Journal of Psychotraumatology

Neuroception of psychological safety scale (NPSS): validation with a UK based adult community sample

Article

作者: Campbell, John ; Irvine Fitzpatrick, Linda ; Young, David ; Porges, Stephen ; Cogan, Nicola ; Ali, Alisha ; De Kock, Johannes ; Morton, Liza ; Lamb, Danielle

Background: Psychological safety plays a vital role in rest, recovery, and fostering social connections. However, a history of trauma can predispose individuals to perceive heightened levels of threat and danger. Research suggests that a lack of psychological safety may be a defining biopsychosocial characteristic of posttraumatic stress disorder (PTSD). Persistent feelings of threat and danger are associated with a lack of psychological safety and may be predictive of PTSD. Our pioneering work reported on the development of the neuroception of psychological safety (NPSS), rooted in polyvagal theory, and consists of social engagement, compassion, and body sensations dimensions. Understanding more about the dimensionality of the NPSS and further establishing its psychometric properties was our priority.Objective: Our current research aimed to validate and test the reliability and dimensionality of the NPSS, using a large community sample (n = 2035) of adult residents in the UKMethod: We examined the internal and test-retest reliability, convergent, discriminant, and concurrent validity as well as dimensionality of the NPSS.Results: The 3-factor structure of the NPSS was replicated with regard to the absolute fit indices. Internal consistencies ranged from acceptable to excellent across the NPSS's subscales. Providing support for the validity of the NPSS, scores were predictably related to team psychological safety, wellbeing, post-traumatic stress, burnout, body awareness, and personality, with effect sizes typically in the high to medium range. Scores on the NPSS were found to show good test-retest reliability.Conclusions: This study demonstrates the validity, reliability and dimensionality of the NPSS with an adult sample. Further work is underway to support and enhance understandings of psychological safety with diverse clinical populations impacted by trauma. The NPSS has applicability across a range of health and social care contexts, such as shaping new approaches to evaluating trauma treatments and enhancing trauma informed care.

项与 Glasgow Caledonian University 相关的新闻（医药）

2023-09-18

·BioSpace

Catalent Appoints David McErlane as Biologics Segment Leader

SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that David McErlane has been named Group President of Catalent’s Biologics segment, effective September 25, 2023. Mr. McErlane joins Catalent from Lonza, where he served as senior vice president and business unit head for Lonza’s Bioscience business. Prior to joining Lonza, Mr. McErlane held several leadership positions at MilliporeSigma and BioReliance after beginning his career as an engineering manager at Zeneca. He holds a bachelor’s degree in electronic systems engineering from Glasgow Caledonian University. “David is a seasoned and highly successful business leader with a record of developing winning strategies that drive growth and create significant value,” said Alessandro Maselli, President and Chief Executive Officer of Catalent. “I am excited to work with David, who I am confident will make an immediate, positive impact on our Biologics business and help take Catalent to its next phase of growth.” Mr. McErlane will lead all of Catalent’s Biologics businesses and global service offerings – including development, drug substance manufacturing, drug product fill-and-finish, cell and gene therapy, and analytical services. About Catalent, Inc. Catalent, Inc. (NYSE: CTLT), is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year. For more information, visit . More products. Better treatments. Reliably supplied.™ View source version on businesswire.com: Contacts Investor Contact: Paul Surdez (732) 537-6325 investors@catalent.com Media Contact: Bernie Clark +1 (732) 537-6400 media@catalent.com Source: Catalent, Inc. View this news release online at:

高管变更

2022-07-20

·Science Daily

A new measure of psychological safety for patients

A new scale for measuring the psychological safety of patients has been developed. A new scale for measuring the psychological safety of patients has been developed at the University of Strathclyde. Researchers devised the scale, consisting of 29 items, to assess how safe a person feels. It is further divided into three sub-scales of Social Engagement, Compassion and Bodily Sensations. The items were identified from the responses to a questionnaire, in which participants were asked how strongly they agreed with 107 statements such as: 'I felt understood'; 'I felt compassion for others,' and 'my heart rate felt steady.' Using statistical methods, the researchers established which statements were most associated with feeling safe, leading to the 29-item scale. The measure, which has been named the Neuroception of Psychological Safety Scale (NPSS), is the first of its kind, combining psychological, physiological and social components. It has the potential to be used in a broad range of settings, such as tracking progress in psychological therapy or assessing whether a sense of psychological safety enhances learning or improves hospital outcomes. It can also be applied to psychological safety in the wake of the COVID-19 pandemic. NPSS is informed by the Polyvagal Theory (PVT), which offers a comprehensive explanation of psychological safety grounded in an evidence base of neurophysiology, psychology and evolutionary theory. The study has been published in the journal Psychological Trauma: Theory, Research, Practice, and Policy. Dr Liza Morton, who led the research, was based at Strathclyde during the study and is now a Lecturer in Applied Psychology in Glasgow Caledonian University's Department of Psychology. She said: "The importance of feeling psychologically safe for health and wellbeing is being increasingly recognised. Feeling psychologically safe is essential for protecting us from stress, anxiety and low mood, while promoting post-traumatic growth following adversity. "When we feel safe, we feel connected and engaged with others and our world and our autonomic nervous system can support the processes of health, growth and restoration. Whereas when we sense threat, our 'fight-flight response' is activated. We feel anxious or angry and a surging energy towards self-defence. Our sensations are heightened and we become vigilant, searching for danger cues, real or imagined. "This improved understanding of the importance of feeling safe has led to an approach I've termed Psychologically Informed Medicine, which aims to foster feelings of safety to improve mental health outcomes for people requiring medical care. This complements my health advocacy, for people like myself, who depend on livelong medical interventions. "We have developed this standardised measure of psychological safety to enhance clinical work and research in this growing field." Dr Nicola Cogan, a Senior Lecturer in Strathclyde's School of Psychological Sciences & Health, is also a co-author of the research. She said: "Clients often seek therapy because they are struggling to feel safe, blighted by anxiety, stress and low mood. They often wish to feel safe again, or indeed yearn to for the first time. "Early adversity and repeated exposure to adverse life events can bias us towards sensing threat, which can significantly challenge feelings of safety and compromise our physical and psychological wellbeing. "Organisations that encourage psychological safety have been found to cultivate adaptive learning, creativity and nourishing relationships, with measurable improvements in peoples' health and wellbeing." The study also involved: partners from the Traumatic Stress Research Consortium at Indiana University's Kinsey Institute, including Professor Stephen Porges, the founder of Polyvagal Theory, and Dr Jacek Kolacz; Strathclyde Teaching Associate Dr Damien Williams and MSc students Calum Calderwood and Marek Nikolac. Dr Thomas Bacon, Clinical Psychologist with NHS Fife, and Dr Emily Pathe, Counselling Psychologist with NHS Lanarkshire, contributed to item development.

100 项与 Glasgow Caledonian University 相关的药物交易

登录后查看更多信息

100 项与 Glasgow Caledonian University 相关的转化医学

登录后查看更多信息